- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07951125
Tranexamic Acid for Recovery After Modified Radical Mastoidectomy in Patients With Chronic Suppurative Otitis Media
Clinical Study on the Application of Tranexamic Acid to Improve the Prognosis of Surgical Treatment for Chronic Suppurative Otitis Media
The main objective of this project is to conduct a multicentre, prospective, randomised, controlled clinical trial to evaluate the clinical value of tranexamic acid in patients undergoing mastoidectomy. The study population consists of patients with chronic suppurative otitis media scheduled to undergo mastoidectomy. They will be randomised in a 1:1 ratio to either the pre-operative intravenous tranexamic acid group or the saline control group; both groups will undergo treatment in accordance with standardised anaesthesia and surgical protocols. The main research components include:
- Evaluation of the dry ear rate: The primary outcome measure was to compare the difference in dry ear rates between the two groups one month post-operatively, in order to verify the effect of tranexamic acid on improving the dry ear rate following mastoidectomy. The assessment of the dry ear rate was carried out by an ENT specialist unaware of the study group allocation via clinical otoscopic examination; a dry ear was defined as the absence of discharge in the ear canal and complete epithelialisation of the mastoid surgical site. The assessment time point for the primary outcome measure was one month post-operatively.
- Postoperative hearing assessment: This will be assessed based on the improvement in hearing at 3 months postoperatively compared with preoperative levels.
- Safety assessment: The safety assessment will primarily include common adverse reactions associated with the use of tranexamic acid (e.g. nausea, vomiting, dizziness) and serious adverse events (e.g. venous thromboembolism, myocardial infarction, epileptic seizures). These will be comprehensively evaluated in conjunction with clinical signs and laboratory tests to ensure the safety and feasibility of the intervention.
Through this study, the project aims to determine whether tranexamic acid can effectively reduce the incidence of dry ear in the early postoperative period following mastoidectomy, and to provide evidence-based support for its clinical implementation.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Haiyan An, MD,PhD
- Numéro de téléphone: +86 135 2155 3036
- E-mail: anhaiyan76@163.com
Lieux d'étude
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 100034
- Peking University First Hospital
-
Contact:
- DongLiang Mu, MD,PhD
- Numéro de téléphone: +86 17810370608
- E-mail: mudongliang@bjmu.edu.cn
-
Beijing, Beijing Municipality, Chine, 100044
- Peking University People's Hospital
-
Contact:
- Haiyan An, MD,PhD
- Numéro de téléphone: +86 135 2155 3036
- E-mail: anhaiyan76@163.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 18-65 years, regardless of sex
- American Society of Anesthesiologists (ASA) physical status I-II
- Patients diagnosed with chronic suppurative otitis media (CSOM) who have had an inadequate response to conservative medical treatment
- Patients scheduled to undergo microscopic open (canal wall-down) radical mastoidectomy
- Patients who provide written informed consent
Exclusion Criteria:
- Known allergy or hypersensitivity to tranexamic acid (TXA)
- Severe hepatic or renal disease (hepatic or renal decompensation); thromboembolic diseases, including deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction; a history of epilepsy, including seizures induced by any cause; or coagulation disorders (any of the following coagulation parameters-activated partial thromboplastin time [APTT], prothrombin time [PT], fibrinogen [FIB], or D-dimer [D-D]-exceeding 1.5 times the upper limit of the normal range)
- Use of anticoagulant or antiplatelet medications within 2 weeks before surgery, including aspirin, clopidogrel, warfarin, or other such medications
- Color blindness, pregnancy, or breastfeeding
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Normal Saline (NS) Group
An equivalent volume of normal saline will be administered intravenously 10 minutes before skin incision. |
An equivalent volume of normal saline will be administered intravenously 10 minutes before skin incision. |
|
Expérimental: Tranexamic Acid (TXA) Group
Tranexamic acid 15 mg/kg will be administered intravenously 10 minutes before skin incision. |
Tranexamic acid 15 mg/kg will be administered intravenously 10 minutes before skin incision. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Dry ear rate
Délai: 1 month (±1 week) after surgery
|
A dry ear is defined as no exudate in the external auditory canal or mastoid cavity and complete epithelialization of the surgical cavity. Dry ear status will be assessed by an otolaryngologist using otoendoscopy. |
1 month (±1 week) after surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Hearing improvement
Délai: 3 months after surgery (±2 weeks)
|
Pure-tone audiometry will be used to assess hearing thresholds at 0.5, 1, 2, and 4 kHz. Air-conduction (AC), bone-conduction (BC), and air-bone gap (ABG) thresholds will be recorded at each frequency. |
3 months after surgery (±2 weeks)
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety and tolerability
Délai: At postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks)
|
Adverse events will be assessed at postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks), including common adverse events such as nausea, vomiting, and dizziness, as well as serious adverse events such as arterial or venous thromboembolism, myocardial infarction, and seizures. These assessments will be used to evaluate the safety of preoperative intravenous administration of tranexamic acid in patients undergoing modified radical mastoidectomy. |
At postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2026PHB663-001
- 首发2026-2-4085 (Autre subvention/numéro de financement: Beijing Municipal Health Commission)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data will not be shared with other researchers due to patient privacy and confidentiality considerations, as well as institutional data protection requirements. Only aggregated study results may be made publicly available through scientific publications.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .